Neutralization of SARS-CoV-2 infection by antibodies targeting diverse epitopes  

作　　者：Shusheng Wang Yunji Liao Kaiyong Yang Hang Ma Zhangyi Song Haiqiu Huang Li Zhang Ailing Wang Lei Han Jiawei Zhang Hui Chen Haiyang Yin Yantin Bian Hua Jiang Xiaodong Xiao Yueqing Xie Yunsheng Yuan Jianwei Zhu 

机构地区：[1]Engineering Research Center of Cell and Therapeutic Antibody,Ministry of Education,School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240,China [2]Jecho Laboratories,Inc.,Frederick,MD 21704,USA [3]Jecho Institute Co.,Ltd.,Shanghai 200240,China

出　　处：《Genes & Diseases》2024年第4期134-137,共4页基因与疾病（英文）

基　　金：the National Natural Science Foundation of China(No.81773621,82073751 to JZ);the National Science and Technology Major Project"Key New Drug Creation and Manufacturing Program"of China(No.2019ZX09732001-019 to JZ);the Key R&D Supporting Program(Special support for developing medicine for infectious diseases)from the Administration of Chinese and Singapore Tianjin Eco-city to Jecho Biopharmaceuticals Ltd.Co.,Zhejiang University special CoVID-19 grant 2020XGZX099;Shanghai Jiao Tong University"Crossing Medical and Engineering"grant 20X190020003 to JZ.

摘　　要：The CoVID-19 pandemic that started in late 2019 is sweeping through the world,posing historic challenges to global health,and disrupting social and economic lives.Previous and recent studies indicate that monoclonal antibodies can be efficacious in preventing and treating SARSCoV-1 and SARS-CoV-2 infections.Using a phage display platform,we have identified dozens of monoclonal antibodies that bind to diverse epitope groups on the SARS-CoV-2 spike protein.Many of them bound to the receptor binding domain(RBD)and inhibited ACE2-RBD interaction.

关 键 词：ANTIBODIES inhibited MONOCLONAL 

分 类 号：R373[医药卫生—病原生物学]